Evaluating Aranesp® in Subjects With End Stage Renal Disease onChronic Hemodialysis
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the Aranesp® dose administered intravenously (IV) once
weekly to maintain hemoglobin (Hgb) levels in hemodialysis subjects who are either
recombinant human erythropoietin (rHuEPO) naïve or subjects converted from rHuEPO therapy
administered IV thrice weekly (TIW).